Aleph-7

Last updated
Aleph-7
Aleph-7.svg
Clinical data
Other namesALEPH-7; 4-Propylthio-2,5-dimethoxyamphetamine; 2,5-Dimethoxy-4-propylthioamphetamine; 4-PrS-DMA
Routes of
administration 		Oral [1]
Drug class Serotonergic psychedelic; Hallucinogen; Monoamine oxidase inhibitor; Reversible inhibitor of MAO-A
ATC code
  • None
Pharmacokinetic data
Duration of action 15–30 hours [1]
Identifiers
  • 1-(2,5-dimethoxy-4-propylsulfanylphenyl)propan-2-amine
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
Formula C14H23NO2S
Molar mass 269.40 g·mol−1
3D model (JSmol)
  • CCCSC1=C(C=C(C(=C1)OC)CC(C)N)OC
  • InChI=1S/C14H23NO2S/c1-5-6-18-14-9-12(16-3)11(7-10(2)15)8-13(14)17-4/h8-10H,5-7,15H2,1-4H3
  • Key:XHWDHFUBCVWXDZ-UHFFFAOYSA-N

Aleph-7, or ALEPH-7, also known as 4-propylthio-2,5-dimethoxyamphetamine, is a psychedelic drug of the phenethylamine, amphetamine, and DOx families. [1] It is one of the Aleph series of compounds. [1]

Contents

In his book PiHKAL (Phenethylamines I Have Known and Loved), Alexander Shulgin lists Aleph-7's dose as 4 to 7 mg orally and its duration as 15 to 30 hours. [1] The effects of Aleph-7 have been reported to include strangeness, slight visual changes, intense but difficult to describe altered states of consciousness, everything feeling "preprogrammed", emotional changes, negative reactions, unwillingness to take the drug again, relaxation, and paresthesia, among others. [1] It was said to produce a "Beth state", defined as a state of uncaring, anhedonia, and emotionlesssness. [1] Many other drugs are also said to have a touch of such a state, but Aleph-7 to have more of it than most. [1]

It is known to be a weak monoamine oxidase inhibitor (MAOI), specifically a reversible inhibitor of MAO-A (RIMA), with an IC50 Tooltip half-maximal inhibitory concentration of 2.4 μM. [2] [3] The chemical synthesis of Aleph-7 has been described. [1]

Aleph-7 was first described in the scientific literature by Shulgin in 1981. [4] [5] Subsequently, it was described in greater detail by Shulgin PiHKAL in 1991. [1] The drug was encountered as a novel designer drug in Europe in 2005. [6]

See also

References

  1. 1 2 3 4 5 6 7 8 9 10 Shulgin, Alexander; Shulgin, Ann (September 1991). PiHKAL: A Chemical Love Story. Berkeley, California: Transform Press. ISBN   0-9630096-0-5. OCLC   25627628. https://erowid.org/library/books_online/pihkal/pihkal007.shtml
  2. ↑ Reyes-Parada M, Iturriaga-Vasquez P, Cassels BK (2019). "Amphetamine Derivatives as Monoamine Oxidase Inhibitors". Front Pharmacol. 10 1590. doi: 10.3389/fphar.2019.01590 . PMC   6989591 . PMID   32038257.
  3. ↑ Gallardo-Godoy A, Fierro A, McLean TH, Castillo M, Cassels BK, Reyes-Parada M, Nichols DE (April 2005). "Sulfur-substituted alpha-alkyl phenethylamines as selective and reversible MAO-A inhibitors: biological activities, CoMFA analysis, and active site modeling". J Med Chem. 48 (7): 2407–2419. doi:10.1021/jm0493109. PMID   15801832.
  4. ↑ Shulgin AT (1980). "Hallucinogens". In Burger A, Wolf ME (eds.). Burger's Medicinal Chemistry. Vol. 3 (4 ed.). New York: Wiley. pp. 1109–1137. ISBN   978-0-471-01572-7. OCLC   219960627.
  5. ↑ Shulgin AT (1982). "Chemistry of Psychotomimetics". In Hoffmeister F, Stille G (eds.). Psychotropic Agents, Part III: Alcohol and Psychotomimetics, Psychotropic Effects of Central Acting Drugs. Handbook of Experimental Pharmacology. Vol. 55. Berlin: Springer Berlin Heidelberg. pp. 3–29. doi:10.1007/978-3-642-67770-0_1. ISBN   978-3-642-67772-4. OCLC   8130916.
  6. ↑ King LA (2014). "New phenethylamines in Europe". Drug Test Anal. 6 (7–8): 808–818. doi:10.1002/dta.1570. PMID   24574327.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.